StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis 4. Cardiovascular, Renal & Metabolic by Year

4. Cardiovascular, Renal & Metabolic ($M)

QuarterlyAnnual

Novartis 4. Cardiovascular, Renal & Metabolic: $8,959M in FY2025, up 4.5% from a year earlier.

Latest, FY2025
8,959
Period ended Dec 31, 2025
Change on a year earlier
+4.5%
8,576 in FY2024
History
4 years
Since FY2022
Sources
3
Documents cited below

Where the FY2025 figure comes from

“|| Total cardiovascular, renal and metabolic | 8 959 | 8 576 | 4 | 3”

Source: Novartis Form 6-K (0001114448-26-000007) ↗

Reported in Form 6-K (Net sales by therapeutic area) & Form 20-F.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEnded4. Cardiovascular, Renal & Metabolic ($M)Year on yearSource
FY2025Dec 31, 20258,959+4.5%Novartis Form 6-K (0001114448-26-000007) ↗
FY2024Dec 31, 20248,576+34.2%Novartis Form 6-K (0001114448-26-000007) ↗
FY2023Dec 31, 20236,390+34.4%Novartis Form 6-K (0001370368-25-000007) ↗
FY2022Dec 31, 20224,756–Novartis Form 6-K (0001370368-24-000007) ↗

Breakdown

What makes up 4. Cardiovascular, Renal & Metabolic

Cite this data

StockData. (2026). Novartis 4. Cardiovascular, Renal & Metabolic ($M), annual FY2022–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/ta-crm

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.